Dominick Escher

Dominik is a founding partner of BB Pureos Bioventures. He is also President of the Swiss Biotech Association and a co-founder and Executive Chairman of CDR-Life. Previously, he was a founder and chief executive officer of ESBATech, which was acquired in 2009 by Alcon (Novartis) for $589 million (USD). As a biotech entrepreneur, he raised $90 million (USD) for ESBATech to develop novel antibody fragments, from discovery to clinical proof-of-concept, delivering multiple clinically successful products (eg, Beovu). Dominik earned his PhD in molecular biology from the University of Zurich and holds a master’s degree in education, with specialization in management and organization from ETH Zürich.